News

Who's being shut down, what's being approved, what the trials actually said. Every story is split into what the record establishes, what it doesn't, and what would change it. No verdicts, no ads, no vendor placements. Sources are graded: primary is the document itself, secondary is a report about it.

The September 21 revision of Import Alert 66-80 broadens detention-without-examination to more peptide product codes and names which foreign API makers have cleared FDA's bar.

1 primary record · 0 secondary

EnforcementOctober 3, 2026Settled record

FDA sends warning letters to five online peptide sellers in one day

Letters dated August 24, 2026 name NuScience Peptides, Royal Peptides, Peptide Partners, Peak Performance Peptides, and TXP Innovations. FDA says 'research use only' labels did not change its reading of intended use.

2 primary records · 1 secondary

LitigationOctober 3, 2026Developing

Lilly files six lawsuits over retatrutide sold before approval

On August 12, 2026 Eli Lilly sued a med spa, a compounding pharmacy, and four online peptide sellers in California and Texas federal courts, and said it has referred more than 200 parties to regulators.

1 primary record · 1 secondary

EnforcementOctober 3, 2026Settled record

Paradigm Peptides owner sentenced to 70 months in federal prison

Matthew J. Kawa pleaded guilty to introducing unapproved new drugs into interstate commerce with intent to defraud. DOJ says the company sold to 54,000 customers and that some products labeled as SARMs were testosterone.

1 primary record · 1 secondary

RegulationOctober 3, 2026Developing

FDA advisory panel recommends six peptides for the compounding list, over staff objections

At its July 23–24, 2026 meeting the Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A Bulks List and against emideltide (DSIP). The vote changes nothing yet.

1 primary record · 2 secondary

Clinical researchOctober 3, 2026Developing

Retatrutide Phase 3: 28.3% mean weight loss at 80 weeks, 11.3% quit the top dose

Lilly's May 21, 2026 topline release for TRIUMPH-1 reports all three doses met primary and key secondary endpoints. The same release reports discontinuation for adverse events rising with dose.

2 primary records · 0 secondary

How the desk works

A story runs only when at least one primary record exists. Reports without a document behind them wait.
We state what the record establishes and, separately, what it does not. The second list is usually the more useful one.
Every story names the evidence that would change it, and carries a dated status: developing, updated, or settled record.
We never take a position on whether a peptide is safe, effective, or worthless. We publish the question. Corrections: corrections@peptides.info.